Patents by Inventor José Luis GARCÍA PUCHE

José Luis GARCÍA PUCHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR THE DETECTION OF CIRCULATING TUMOUR CELLS, BOTH CIRCULATING TUMOUR CELLS OF THE EPITHELIAL PHENOTYPE AND CIRCULATING TUMOUR CELLS HAVING EPITHELIAL-MESENCHYMAL TRANSITION (EMT) MARKERS, USING THE MIRNA-21 AS A BIOMARKER
    Publication number: 20170321261
    Abstract: The present invention provides an in vitro method of detecting circulating tumour cells, circulating tumour cells of epithelial phenotype and circulating tumour cells of epithelial to mesenchymal transition (EMTs), in a biological sample using, as an indicator, expression levels of miRNA-21, and obtaining a result of the method by comparing the expression levels of said miRNA-21 with a negative control or with a positive control, wherein if the expression levels in the cells of the biological sample are over-expressed in comparison to a negative control is indicative of the presence of circulating tumour cells in said biological sample or wherein if the expression levels in the cells of the biological sample are expressed in an amount greater than ? of the maximum expression achieved in a positive control is indicative of the presence of circulating tumour cells in said biological sample.
    Type: Application
    Filed: September 18, 2015
    Publication date: November 9, 2017
    Inventors: María José SERRANO FERNÁNDEZ, Juan José DÍAZ MOCHÓN, Francisco GABRIEL ORTEGA, José Antonio LORENTE ACOSTA, José Luis GARCÍA PUCHE, Maria Paz RUIZ BLAS, Rosario María SÁNCHEZ MARTÍN
  • EPITHELIAL-MESENCHYMAL TRANSITION IN CIRCULATING TUMOR CELLS (CTCS) NEGATIVES FOR CYTOKERATIN (CK) EXPRESSION IN PATIENTS WITH NON-METASTATIC BREAST CANCER
    Publication number: 20160273047
    Abstract: The inventors of the present invention have surprisingly discovered that EGFR expression in nonmetastatic breast cancer patients with CK-negative CTCs could induce EMT process. A simultaneous detection of both EGFR and EMT markers (VIM and Slug) in CTCs might improve prognostic or predictive information in patients with operable breast cancer.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 22, 2016
    Inventors: José Luis GARCÍA PUCHE, María José SERRANO FERNÁNDEZ, José Antonio LORENTE ACOSTA, Juan Antonio MARCHAL CORRALES, Francisco Gabriel ORTEGA SÁNCHEZ